



Pharmacological Therapies for Stress-Related Disorders and Autism Spectrum Disorder

Guest Editors:

Dr. Anita Kovács

Medical School, Institute of
Physiology, University of Pécs,
Szigeti Str. 12, P.O. Box 99, 7602
Pécs, Hungary

Dr. Attila Tóth

Medical School, Institute of
Physiology, University of Pécs,
Szigeti Str. 12, P.O. Box 99, 7602
Pécs, Hungary

Deadline for manuscript
submissions:

21 July 2024

Message from the Guest Editors

Selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) are the first choice as pharmacological treatment of anxiety disorder in the general population. Depression disorder is a common heterogeneous mental disease that affects all aspects of patients' lives, as well as people around them. Nowadays, ADs are divided into five classes: SSRIs, SNRIs, TCAs, MAOIs and atypical ADs with unique mechanisms of action. The development of new drugs and methods for depression treatment is critical. The current therapy for anxiety in ASD includes cognitive–behavioral therapy and psychopharmacological treatment.

In this Special Issue, we want to expand the knowledge on antidepressant drugs and their mechanism of action. Pharmacological interventions show promise for typically developing populations, but further research is needed to establish the efficacy of medications for individuals. Because comorbid ASD/anxiety remains a nascent and developing area of study, practitioners are encouraged to publish the latest scientific findings.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com